HSF1による腫瘍ストロマの再プログラミングは,悪性腫瘍の強力な促進剤です
Ruth Scherz-Shouval1, Sandro Santagata2, Marc L Mendillo1
1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Cell
|August 2, 2014
まとめ
熱ショック因子1 (HSF1) が癌に関連した線維芽細胞 (CAFs) の再プログラミングにより,腫瘍の進行が促進されます. このCAF主導のプログラムは,がん細胞とは異なり,悪性腫瘍を強め,早期がんの患者さんの不良結果を予測します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- がん研究 がん研究
背景:
- 腫瘍の微小環境のストロマ細胞は,がんの進行と転移に極めて重要です.
- ストロマ細胞の転写再プログラミングを駆動する要因は,ほとんど不明のままである.
- 熱ショック因子1 (HSF1) は,細胞のストレス反応における既知の役割を持つ転写調節因子である.
研究 の 目的:
- 癌に関連した線維芽細胞 (CAFs) でのHSF1の役割を調査する.
- CAFにおけるHSF1によって駆動される転写プログラムを解明する.
- 癌におけるストロマルHSF1活性化の臨床的意義を決定する.
主な方法:
- 腫瘍組織内のCAFにおけるHSF1活性化の分析.
- HSF1活性化および無活性化によるCAFの転写プロファイリング.
- 乳がんと肺がんの初期段階における患者のアウトカムと,ストロマのHSF1活性化の相関分析.
主要な成果:
- HSF1はCAFで頻繁に活性化され,悪性腫瘍の強力な活性化剤として作用します.
- HSF1は,悪性腫瘍を非細胞自律的にサポートするユニークなCAF転写プログラムを駆動します.
- ストロマルのHSF1活性化は,乳がんと肺がんの初期段階での患者の不良の結果と強く関連しています.
- 主要なストロマ信号分子であるTGF-βとSDF1は,この過程で重要な役割を果たします.
結論:
- 腫瘍はHSF1の生存機能を乗っ取り,細胞自律的および非細胞自律的メカニズムの両方を通じて悪性腫瘍を促進します.
- CAFにおけるHSF1をターゲットにすることは,潜在的な治療戦略です.
- 腫瘍の微環境におけるHSF1の役割を理解することは,重要な治療的影響を及ぼします.
関連する概念動画
The Tumor Microenvironment
6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Somatic to iPS Cell Reprogramming
2.0K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.0K
Regulation of Hematopoietic Stem Cells
3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Cancer Stem Cells and Tumor Maintenance
4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer Stem Cells and Tumor Maintenance
2.0K
2.0K


